RNA

Cas9 mRNA（5'CAP）は、in vitro転写によって産生されるDNAエンドヌクレアーゼmRNAです。Cap 1キャップ構造とポリ（A）テールを持っています。

N1-Me-pUTP（5'CAP）を含むCas9 mRNAは、in vitro転写によって生成されるDNAエンドヌクレアーゼmRNAです。Cap 1キャップ構造とポリ(A)テールを持ち、N1-Me-pUTP修飾が含まれています。

Cy5 Cas9 mRNA (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 Cas9 mRNA (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 Cas9 mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 Cas9 mRNA with N1-Me-pUTP (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 eGFP mRNA with N1-Me-pUTP (5'CAP) is a green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 eGFP mRNA with N1-Me-pUTP (5’CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 eGFP mRNA (5'CAP) is a green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 eGFP mRNA (5'CAP) carries Cy5 labeling(Cy5-UTP: UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, which can effectively inhibit RNA mediated innate immune activation.

Cy5 Fluc mRNA with N1-Me-pUTP (5'CAP) is a luciferase mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc mRNA with N1-Me-pUTP (5'CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, which enhances mRNA stability and translation efficiency.

Cy5 Fluc mRNA (5'CAP) is a luciferase mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc mRNA (5'CAP) carries the Cy5 label (Cy5-UTP:UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, and can effectively inhibit RNA mediated innate immune activation.

Cy5 Fluc-eGFP mRNA with N1-Me-pUTP (5'CAP) is a luciferase green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc-eGFP mRNA with N1-Me-pUTP(5’CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 Fluc-eGFP mRNA (5'CAP) is a labeled luciferase green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc-eGFP mRNA (5'CAP) carries the Cy5 label(Cy5-UTP: UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 mCherry mRNA (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 mCherry mRNA (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 mCherry mRNA with N1-Me-pUTP (5'CAP) is a fluorescent reporter gene commonly used in molecular biology research. Cy5 mCherry mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, it has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 OVA mRNA (5'CAP) is produced through in vitro transcription, which simulates the mRNA processing process in eukaryotes. It has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), increasing the stability and translation efficiency of mRNA^[1].

Cy5 OVA mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing in eukaryotes, it has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

N1-Me-pUTP（5'CAP）を用いたFluc mRNAは、in vitro転写によって生成されるルシフェラーゼmRNAであり、Cap 1キャップ構造とポリ(A)テールを持ち、N1-Me-pUTP修飾が含まれています。

Fluc-eGFP mRNAは、N1-Me-pUTPを用いてin vitro転写されたルシフェラーゼmRNAであり、Cap 1キャップ構造とポリ(A)テールを持ち、N1-Me-pUTP修飾が含まれています。

Fluc-eGFP mRNA（5'CAP）は、in vitro転写によって産生されたルシフェラーゼmRNAであり、Cap 1キャップ構造とポリ(A)テールが付与されています。

mCherry mRNAは、分子生物学研究において一般的に使用される蛍光報告遺伝子であり、Cap 1キャップ構造とポリ(A)テールを持ち、N1-Me-pUTP修飾が含まれています。

オーバルブミンOVA mRNA（5'CAP）は、in vitro転写によって生成され、Cap 1キャップ構造とポリ（A）テールを持っています。

N1-Me-pUTP（5'CAP）を持つOVA mRNAは、in vitro転写によって産生された卵白質mRNAであり、Cap 1キャップ構造とポリ(A)テールを有し、N1-Me-pUTP修飾を含んでいます。

TRIzol LS試薬は、液体サンプル（細菌、ウイルス、酵母、細胞、血液、組織懸濁液など）から高品質のRNAを抽出するために特別に使用される試薬です。

TRIzol NC試薬はクロロホルムを使わない完全なRNA抽出試薬で、培養細胞、動物の組織と植物組織に広く適している。